aldosterone synthase inhibitor - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

Read More

Pharma Industry News

New Baxdrostat Phase III data reveal significant ambulatory blood pressure reduction in resistant patients

Find out how AstraZeneca’s Baxdrostat achieved significant blood pressure reductions in resistant hypertension patients in Phase III trials.

bySoujanya Ravi

November 10, 2025

web analytics